Roche gets hit with another big R&D setback as a prospective AMD blockbuster flops in PhIII
At one point Genentech’s eye drug lampalizumab was a comfort to Roche CEO Severin Schwan as he contemplated the loss of patent protection on the …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
